Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 9, 2026

Horizon Quantum Announces Expected New Board Members and Chief Legal Officer

View original at finance.yahoo.com
Horizon Quantum Announces Expected New Board Members and Chief Legal Officer SINGAPORE, March 09, 2026--(BUSINESS WIRE)--Horizon Quantum Holdings Ltd…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bringing world-class appointments to the board and leadership team strengthens the company and enhances ability to achieve mission of unlocking the full potential of quantum computers

    80% confidence
  • Catherine Fitzsimons will be an outstanding addition to the team with her strong legal experience, particularly at Fidelity International

    80% confidence
  • Joining presents a compelling opportunity to support the business through a period of transformation

    80% confidence
  • The momentum across the quantum industry, together with Horizon Quantum's next stage of growth, makes this a particularly exciting time to join the Company

    80% confidence
  • Catherine Fitzsimons will be an excellent steward for the Company and all of its stakeholders, especially its new public shareholders

    80% confidence
  • Horizon Quantum is entering a crucial next phase of growth as they prepare to go public via a definitive business combination agreement with dMY

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com